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Neprilysin (NEP) inhibition has become an 
important issue in cardiology and pulmonology. 
Among others, it is reflected by the constantly 
growing number of articles discussing this topic 
found on PubMed. However, it is worth exploring 
the multidimensional role of Neprilysin, as well 
as its inhibition in many diseases. Our article 
also tackles the issue of unexpected complica-
tions that may develop in patients with chronic 
obstructive pulmonary disease (COPD) due to 
NEP inhibition.
The problem with assessing safety and ad-
verse reactions of neprilysin inhibitors results 
from the enzyme’s multifunctional nature. Neu-
tral endopeptidase 24.11 is responsible for metab-
olizing numerous substances which often act in 
opposition to each other. Therefore, when plan-
ning studies in this area it must be remembered 
that NEP is not only associated with metabolism 
of natriuretic peptides but is also related to nu-
merous pleiotropic mechanisms. 
Right ventricular failure is one of the most 
serious complications of COPD which signifi-
cantly deteriorates prognosis in this disease [1]. 
Therefore, due to the confirmed efficacy in heart 
failure therapy (PARADIGM-HF), administration 
of angiotensin receptor-neprilysin inhibitors 
(ARNI) in this group of patients may bring consid-
erable therapeutic benefits that exceed possible 
adverse reactions. The PARADIGM-HF study that 
involved a group of more than eight thousand 
subjects proved the advantages of ARNI therapy 
in patients with HFrEF as compared to ACEI. In 
the group of patients receiving ARNI the observed 
mortality caused by cardiovascular problems, as 
well as the number of first hospitalizations due 
to HF, were lower than in the case of enalapril 
therapy (21.8% vs 26.5%) [2, 3].
The efficacy of ARNI therapy is not limited 
to HFrEF only. The Paramount study focused 
on HfpEF patients. Entresto decreased the level 
of N-terminal pro-B-type natriuretic peptide 
(NT-proBNP) as compared to valsartan, however, 
this difference was not statistically significant 
after 36 weeks of the study. Nevertheless, it is 
worth remembering that Entresto decreased the 
left atrial volume and size to a greater extent [2, 3].
We are still waiting for the results of the 
PARAGON-HF trial which is to verify the effica-
cy of HfpEF therapy with the use of sacubitril/ 
/valsartan in over four thousand patients under 
planned monitoring for 57 weeks [2]. 
The potential adverse reactions involving the 
respiratory system include bronchoconstriction, 
which is among others related to inhibition of 
metabolism of P substance, neurokinin A and 
bradykinin [3].
Apart from its vasodilatory properties, bra-
dykinin at high levels induces airway smooth 
muscle contraction. It is also a pro-inflammatory 
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mediator and may cause angioedema [4]. There-
fore, there is a reasonable concern that neprilysin 
inhibitors may increase the level of bradykinin in 
the lungs and exacerbate symptoms in patients 
suffering from asthma or COPD. On the other 
hand, neutral endopeptidase 24.11 causes an in-
crease in the level of natriuretic peptides having 
bronchodilatory and immunosuppressive proper-
ties, which could lessen the effect of bradykinin 
action [5]. Moreover, there are studies suggesting 
that natriuretic peptides, as natural antagonists of 
B2R signaling pathway may decrease the harmful 
consequences of BK activity [6]. De Gouw et al. [7] 
conducted a  study in which he assessed exer-
cise-induced bronchoconstriction triggered in 
asthmatic patients who were administered NEP/
thiorphan inhibitor prior to an exercise stress 
test. In these patients bronchoconstriction was 
not more aggravated than in a placebo group, 
and during the convalescence period it was even 
lower. 
In the patients treated with the medici-
nal product Entresto (sacubitril/valsartan), an 
occurrence of angioedema was reported. The 
PARADIGM-HF study showed that the number 
of confirmed angioedema cases for sacubitril/ 
/valsartan as compared to enalapril during a dou-
ble-blind trial was 19 (0.45%) vs 10 (0.24%) (the 
relative risk was 1.9 [95%CI 0.8–4.5], thus the 
risk of occurrence of this adverse reaction was 
assessed as low. It is worth mentioning that no 
increased risk of angioedema was observed in 
current smokers administered sacubitril/valsar-
tan or enalapril [8].
Another potentially harmful effect brought 
by neprilysin inhibition is suppression of En-
dotelin-1 metabolism. ET-1 is a peptide with 
strong vasoconstrictive properties which exerts 
a long-term effect on vascular smooth muscle cell 
(VSMC) proliferation and their phenotype [9]. 
Through ETA and ETB receptors, ET-1 stimulates 
pulmonary fibroblast proliferation, which makes 
it an important compound that plays its role in 
pulmonary vascular remodeling and pathology 
of pulmonary hypertension [10]. On the other 
hand, neprilysin inhibition leads to an increase 
in natriuretic peptides which suppress various 
growth factor-stimulated VSMC migration and 
proliferation, hinder fibroblast proliferation and 
extracellular matrix production, in particular 
CNP. In addition, CNP suppresses ET-1 secretion 
from endothelial cells [11]. Kohno et al. [12] 
showed that ANP and BNP suppress secretion of 
endothelin-1 following Ang II stimulation, prob-
ably through a cGMP-dependent process.
We also managed to find scientific evidence 
proving that NEP inhibition reduces the right ven-
tricular hypertrophy which is a serious complica-
tion of pulmonary hypertension. Klinger et al. [13] 
showed that neutral endopeptidase 24.11 inhibi-
tion attenuates development of hypoxic pulmonary 
hypertension in rats. The study revealed a lower 
systolic pressure of the right ventricle, lower right 
ventricle weight-to-left ventricle+septum weight 
ratio and a decreased muscularization and percent 
medial wall thickness of the peripheral pulmonary 
arteries than in rats treated with vehicle only. An-
other study on rats with hypoxic pulmonary hyper-
tension showed that a short-term NEP suppression 
causes a regression of pulmonary vascular remod-
eling and may be a useful therapeutic strategy in 
pulmonary hypertension treatment [14]. 
However, we may also find studies which 
show a reduced NEP expression in the lungs of 
patients with COPD and pulmonary vessel re-
modeling, and strategies aimed at increasing the 
level/expression of NEP may bring therapeutic 
benefits related to prevention and treatment of 
pulmonary hypertension [15].
As we mentioned in our article, the role of 
neprilysin as a factor responsible for amyloid-beta 
degradation is well known. However, NEP is not 
the only protein responsible for amyloid beta deg-
radation. This function is also fulfilled by cathep-
sin G and insulin degrading enzyme [16, 17]. 
Moreover, Maarouf CL and colleagues suggest it 
is the liver that plays the key role in amyloid-beta 
metabolism. In that study NEP expression in the 
human liver homogenates was evaluated with 
the use of western blot method and it was shown 
that there were no significant differences in the 
protein expression in healthy subjects as com-
pared to patients with Alzheimer’s disease [16]. 
It is also worth mentioning that according to the 
most recent findings [18, 19] heart failure may be 
a risk factor in Alzheimer’s disease as a result of 
a reduced cerebral blood flow and neurohormon-
al activation, which leads to the cardiovascular 
system malfunction. There is no hard research or 
clinical data on potential exacerbation or an in-
creased risk of Alzheimer’s disease development. 
It is also worth remembering that Food and Drug 
Administration (FDA) required that NOVARTIS 
company conducted a multicenter randomized, 
double-blind, active-controlled trial to evaluate 
the influence of sacubitril/valsartan on the cogni-
tive functions in patients with chronic HFpEF. It 
analyzed the cognitive functions based on neuro-
cognitive tests and positron emission tomography. 
The study is expected to be completed in 2022 [3].
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It must be remembered that many articles 
on potential negative effects of NEP inhibition in 
patients with COPD are based on animal models, 
which number was not large enough, therefore, 
there is still no strong scientific evidence in this 
field. The fact that information on neprilysin 
inhibition in potential pulmonological patients 
presented in research publications is so ambigu-
ous suggests that there is a strong need to develop 
studies in this respect. 
Our team is going to apply for a grant to con-
duct a study on the influence of ARNI therapy 
on exacerbation of COPD in patients with RHF 
at the stable stage of the disease. Considering the 
studies that indicate the ambiguous impact of 
NEP inhibition in these patients, we will monitor 
the subjects’ levels of PDGF, PDGFR, ET-1, FGF-2, 
BNP, NT-proBNP and NEP. We will also try to 
identify characteristic features of pulmonary 
hypertension in ECG tests. 
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